Skip to main content

Drug Interactions between efgartigimod alfa and measles virus vaccine / rubella virus vaccine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

measles virus vaccine efgartigimod alfa

Applies to: measles virus vaccine / rubella virus vaccine and efgartigimod alfa

GENERALLY AVOID: The safety, immunogenicity, and efficacy of live, attenuated viral or bacterial vaccines during treatment with a neonatal Fc receptor (FcRn) blocker like efgartigimod alfa or rozanolixizumab have not been evaluated. FcRn blockers can cause a transient reduction in IgG levels. In addition, efgartigimod alfa may decrease white blood cell, lymphocyte, and neutrophil counts. Administration of live, attenuated viral or bacterial vaccines during treatment with FcRn blockers may theoretically increase the risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Increased adverse reactions and decreased or suboptimal immunologic response to vaccines may also occur.

MANAGEMENT: Immunization with live, attenuated viral or bacterial vaccines is not recommended during treatment with FcRn blockers. The need to administer age-appropriate vaccines according to immunization guidelines should be assessed prior to initiation of a new treatment cycle with FcRn blockers. It is advisable to complete recommended vaccinations before starting FcRn blockers to avoid potential effects of the medication on immunologic response to vaccines.

References

  1. (2022) "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc.
  2. (2023) "Product Information. Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase)." argenx US Inc.
  3. (2023) "Product Information. Rystiggo (rozanolixizumab)." UCB Pharma Inc

Switch to consumer interaction data

Major

rubella virus vaccine efgartigimod alfa

Applies to: measles virus vaccine / rubella virus vaccine and efgartigimod alfa

GENERALLY AVOID: The safety, immunogenicity, and efficacy of live, attenuated viral or bacterial vaccines during treatment with a neonatal Fc receptor (FcRn) blocker like efgartigimod alfa or rozanolixizumab have not been evaluated. FcRn blockers can cause a transient reduction in IgG levels. In addition, efgartigimod alfa may decrease white blood cell, lymphocyte, and neutrophil counts. Administration of live, attenuated viral or bacterial vaccines during treatment with FcRn blockers may theoretically increase the risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Increased adverse reactions and decreased or suboptimal immunologic response to vaccines may also occur.

MANAGEMENT: Immunization with live, attenuated viral or bacterial vaccines is not recommended during treatment with FcRn blockers. The need to administer age-appropriate vaccines according to immunization guidelines should be assessed prior to initiation of a new treatment cycle with FcRn blockers. It is advisable to complete recommended vaccinations before starting FcRn blockers to avoid potential effects of the medication on immunologic response to vaccines.

References

  1. (2022) "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc.
  2. (2023) "Product Information. Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase)." argenx US Inc.
  3. (2023) "Product Information. Rystiggo (rozanolixizumab)." UCB Pharma Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer